Entity > Corporation > US > New York City New York > Ardelyx

About Ardelyx

Ardelyx, Inc. is a biopharmaceutical company that discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally.

Ardelyx's Lead Product is IBSRELA® (tenapanor): Tenapanor has completed the Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation and the Phase III clinical trial for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis or hyperphosphatemia. IBSRELA (tenapanor) is a prescription medication that works in three ways to treat irritable bowel syndrome with constipation (IBS-C) in adults - it softens stool and speeds bowel movements to improve constipation, it improves leaky gut to reduce abdominal pain, and it reduces the activity of pain-sensing nerves in the gut to reduce abdominal pain.

RDX013 Is Being Developed For Hyperkalemia: Ardelyx is also developing RDX013, a potassium secretagogue, to treat elevated serum potassium, or hyperkalemia, a problem in certain patients with kidney and/or heart disease. Unlike current treatments that bind potassium, RDX013 represents a novel mechanism and targeted therapy that, if successfully approved, could create an entirely new treatment paradigm for patients with hyperkalemia.

Ardelyx Builds Partnerships Globally: The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Industry: Business & Industrial > Pharmaceuticals & Biotech

More information about Ardelyx

Company Attribute Value
Address StreetAddress: 34175 Ardenwood Blvd Ste 200, AddressLocality: Fremont, AddressRegion: California, PostalCode: 94555, AddressCountry: United States
Founding Date 2007
Name Ardelyx
Number Of Employees 86
Revenue $3,983,000 USD
Ticker Symbol NASDAQ: ARDX
Url ardelyx
Facebook facebook
Linkedin linkedin
Twitter twitter
Google google
Wikidata wikidata



New York City, US
13 Jul 2024

New York City, US
13 Jul 2024


Page: 1 Desktop | Laptop Devices
Ardelyx: Home
Translating Scientific Breakthroughs into Promise for Patients. From discovery through commercialization, all of us at Ardelyx® are driven to advance patient ... › quote › ARDX
Ardelyx, Inc. (ARDX) Stock Price, News, Quote & History
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in ...
Ardelyx (@ardelyx) · X › ardelyx › jobs
Ardelyx Careers
Ardelyx Careers · Accounting & Finance. 3 Jobs. Manager, Financial Reporting Compliance · Clinical. 1 Job. Clinical Records Specialist · Information Technology. › ... › United States
ARDX Stock Price | Ardelyx Inc. Stock Quote (U.S.: Nasdaq)
Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also ...
We're committed to creating a sense of belonging, so that everyone can feel comfortable bringing their true authentic self to work. As we celebrate the LGBTQIA+ ...
Ardelyx, Inc.
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet ...
Related Searches
Related Searches
Ardelyx news
Ardelyx cafepharma
Ardelyx FDA approval
Knowledge Panel
Knowledge Panel

Ardelyx Inc (Biotechnology company)

  • Stock price : ARDX (NASDAQ) $5.89 +0.07 (+1.20%)Jul 12, 4:00 PM EDT - Disclaimer
  • CEO : Mike Raab (Mar 2009–)
  • Date founded : 2007
  • President : Mike Raab
  • Headquarters : Waltham, MA

All information on this page is taken from publicly available sources, and the analysis we provide is a representation of Google's search results for the entity and does not represent any opinion or judgement about the entity by Kalicube itself. If you disagree with this analysis, please contact us and cite this reference : 193767